Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites

M. A. Posencheg, A. J. Gow, W. E. Truog, R. A. Ballard, A. Cnaan, S. G. Golombek, P. L. Ballard

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
JournalJournal of Perinatology
Volume30
Issue number4
DOIs
StatePublished - Apr 2010

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Keywords

  • Bronchopulmonary dysplasia
  • NO CLD trial
  • Nitrite

Fingerprint Dive into the research topics of 'Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites'. Together they form a unique fingerprint.

Cite this